GUEST EDITOR

Oncogene (2003) **22**, v. doi:10.1038/sj.onc.1207370

John C. Reed, MD, PhD

Dr John C. Reed is a leader in apoptosis research, and the President of The Burnham Institute, a non-profit biomedical research institute located in La Jolla, CA. He has been a pioneer in delineating the fundamental mechanisms that regulate programmed cell death, and defining their relevance to cancer. Dr. Reed is author of over 600 peer-reviewed scientific articles and over 50 book chapters. He has the distinction of having published more papers on apoptosis during the past decade than any other scientist worldwide, and is among the world's most highly cited scientists, according to The Institute for Scientific Information. Dr. Reed's research discoveries have spawned numerous drug-discovery programs aimed at overcoming apoptosis-resistance in cancers. His DNA-based strategy for targeting of the BCL2 gene recently completed Phase III clinical testing for patients with treatment-refractory cancers. Dr. Reed currently serves on the editorial boards of over 12 scientific journals. He has also served in various capacities as an advisor to the National Cancer Institute (NCI), American Cancer Society (ACS), and the American Association for Cancer Research (AACR). He is the recipient of numerous awards for his research accomplishments, and has been awarded over 50 research grants by a variety of funding agencies, including the National Institutes of Health, the NCI, the ACS, the Leukemia Society of America, CaP-CURE, and the Susan B Komen Breast Cancer Foundation.